Maintenance therapy after Autologous Stem Cell Transplantation in Multiple Myeloma – currents and perspectives

Krzysztof Żyłka; Lidia Gil; Dominik Dytfeld

doi:10.20883/medical.e934

Authors

Krzysztof Żyłka The Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poland https://orcid.org/0009-0003-0893-5038
Lidia Gil The Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poland https://orcid.org/0000-0003-0700-3637
Dominik Dytfeld The Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poland https://orcid.org/0000-0003-0855-6591

DOI:

https://doi.org/10.20883/medical.e934

Keywords:

newly-diagnosed, ASCT, MRD, Autologous Stem Cell Transplant, anti-CD38, maintenance, high-risk, Multiple Myeloma, immunomodulatory therapeutics, proteasome inhibitors

Abstract

MM is non-curable cancer that arises from plasma cells and is the second most common type of blood cancer. Drug-refractory relapses are inevitable, making it essential to sustain long-lasting remissions as part of therapy. Lenalidomide maintenance until progression is a standard of care for transplant-eligible newly-diagnosed patients. However, poor outcomes of high-risk patients and the risk of secondary primary malignancies associated with maintenance underline the need for novel approaches. Significant changes in frontline treatment maintenance are expected, with the increasing importance of minimal residual disease monitoring and the development of novel drug combinations for maintenance. This article explores current standards and prospects for maintaining response after upfront in ASCT in MM.

Downloads

Download data is not yet available.

References

van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. The Lancet. 2021 Jan;397(10272):410–27. doi: 10.1016/S0140-6736(21)00135-5.

Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019 Jan;20(1):57–73. doi: 10.1016/S1470-2045(18)30687-9.

McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine. 2012 May 10;366(19):1770–81. doi: 10.1056/NEJMoa1114083.

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine. 2012 May 10;366(19):1782–91. doi: 10.1056/NEJMoa1114138.

McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. Journal of Clinical Oncology. 2017 Oct 10;35(29):3279–89. doi: 10.1200/JCO.2017.72.6679.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet. 2019 Jan;393(10168):253–64. doi: 10.1016/S0140-6736(18)33003-4.

Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021 Dec;22(12):1705–20. doi: 10.1016/S1470-2045(21)00535-0.

Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 Feb;24(2):139–50. doi: 10.1016/S1470-2045(22)00738-0.

Rosiñol L, Oriol A, Ríos R, Blanchard MJ, Jarque I, Bargay J, et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023 Nov 2;142(18):1518–28. doi: 10.1182/blood.2022019531.

Moreau P, Sonneveld P. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. Journal of Clinical Oncology. 2021 May 20;39(15_suppl):8004–8004. doi: 10.1200/JCO.2021.39.15_suppl.8004.

Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct;10(10):e825–37. doi: 10.1016/S2352-3026(23)00217-X.

Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial. Blood. 2023 Nov 21;142(Supplement 2):LBA-1-LBA-1. doi: 10.1182/blood-2023-191911.

Ragon BK, Shah MV, D’Souza A, Estrada-Merly N, Gowda L, George G, et al. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 Jun 27;7(12):2746–57. doi: 10.1182/bloodadvances.2022009138.

de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology. 2022 Sep 1;40(25):2889–900. doi: 10.1200/JCO.21.02228.

Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology. 2022 Sep 1;40(25):2901–12. doi: 10.1200/JCO.21.01935.

Derman BA, Major A, Major S, Wolfe BD, Gorski M, Cooperrider JH, et al. Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP). Blood. 2022 Nov 15;140(Supplement 1):2108–9. doi: 10.1182/blood-2022-158643.

Kubicki T, Dytfeld D, Wrobel T, Jamroziak K, Robak P, Czyz J, et al. Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM). Blood. 2023 Nov 28;142(Supplement 1):4715–4715. doi: 10.1182/blood-2023-189850.

Panopoulou A, Cairns DA, Holroyd A, Nichols I, Cray N, Pawlyn C, et al. Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood. 2023 Apr 6;141(14):1666–74. doi: 10.1182/blood.2022018339.

Nooka AK, Joseph NS, Dhodapkar M V., Hofmeister CC, Gupta VA, Andrews JS, et al. Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in. Journal of Clinical Oncology. 2023 Jun 1;41(16_suppl):8001–8001. doi: 10.1200/JCO.2023.41.16_suppl.8001.

Joseph NS, Kaufman JL, Dhodapkar M V., Hofmeister CC, Almaula DK, Heffner LT, et al. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology. 2020 Jun 10;38(17):1928–37. doi: 10.1200/JCO.19.02515.